NewAmsterdam Pharma (NAMS) News Today $17.27 +0.48 (+2.86%) Closing price 04/23/2025 04:00 PM EasternExtended Trading$17.22 -0.05 (-0.29%) As of 04/23/2025 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period 1,016,076 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Purchased by Capital World InvestorsCapital World Investors acquired a new stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 1,016,076 shares of the company's stock, valueApril 24 at 5:23 AM | marketbeat.comIs NewAmsterdam Pharma Company N.V. (NAMS) Among the Best Guru Stocks to Buy According to Wall Street Analysts?April 23 at 2:35 PM | insidermonkey.comRock Springs Capital Management LP Purchases 414,203 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)Rock Springs Capital Management LP increased its holdings in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 117.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 767,522 shares of theApril 23 at 6:56 AM | marketbeat.comBain Capital Life Sciences Investors LLC Acquires 245,197 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)Bain Capital Life Sciences Investors LLC boosted its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 2.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,719,110 shares of the company's stock after acquiring an additApril 23 at 6:54 AM | marketbeat.comCapital International Investors Takes Position in NewAmsterdam Pharma (NASDAQ:NAMS)Capital International Investors acquired a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 2,062,535 sharesApril 23 at 4:52 AM | marketbeat.comReviewing NewAmsterdam Pharma (NASDAQ:NAMS) & Cyclerion Therapeutics (NASDAQ:CYCN)April 23 at 2:06 AM | americanbankingnews.comNewAmsterdam Pharma (NASDAQ:NAMS) Short Interest UpdateNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 5,340,000 shares, an increase of 23.0% from the March 15th total of 4,340,000 shares. Based on an average daily volume of 996,300 shares, the short-interest ratio is presently 5.4 days. Approximately 9.4% of the company's shares are sold short.April 22 at 12:12 PM | marketbeat.comNewAmsterdam Pharma Appoints Adele Gulfo to BoardApril 17, 2025 | tipranks.comNewAmsterdam Pharma Appoints Adele Gulfo to its Board of DirectorsApril 17, 2025 | gurufocus.comNewAmsterdam Pharma Co NV (NAMS) Appoints Adele Gulfo to Board of Directors | NAMS stock newsApril 17, 2025 | gurufocus.comAffinity Asset Advisors LLC Sells 47,390 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)Affinity Asset Advisors LLC lowered its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 10.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 425,000 shares of the company's stock after selling 47,April 17, 2025 | marketbeat.comArrowstreet Capital Limited Partnership Acquires New Shares in NewAmsterdam Pharma (NASDAQ:NAMS)Arrowstreet Capital Limited Partnership bought a new position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 30,504 shares of the company's stock, valued at approximateApril 14, 2025 | marketbeat.comNewAmsterdam Pharma (NAMS): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside PotentialApril 11, 2025 | msn.comCenterBook Partners LP Purchases 122,894 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)CenterBook Partners LP increased its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 143.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 208,589 shares of the company's stock after acquiriApril 11, 2025 | marketbeat.comNewAmsterdam Pharma's (NAMS) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $42.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday.April 10, 2025 | marketbeat.comNewAmsterdam Pharma Company (NAMS) Receives a Buy from TD CowenApril 9, 2025 | markets.businessinsider.comNewAmsterdam Pharma (NASDAQ:NAMS) Sets New 52-Week Low - Here's WhyNewAmsterdam Pharma (NASDAQ:NAMS) Reaches New 1-Year Low - What's Next?April 9, 2025 | marketbeat.comNewAmsterdam Pharma Company (NAMS) Gets a Buy from NeedhamApril 9, 2025 | markets.businessinsider.com4NAMS : The Analyst Verdict: NewAmsterdam Pharma Co In The Eyes Of 6 ExpertsApril 8, 2025 | benzinga.comOvata Capital Management Ltd Takes Position in NewAmsterdam Pharma (NASDAQ:NAMS)Ovata Capital Management Ltd purchased a new position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 150,000 shares of the company's stock, valued at aApril 7, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Receives Consensus Recommendation of "Buy" from AnalystsNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) has received an average rating of "Buy" from the six analysts that are covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have issued aApril 7, 2025 | marketbeat.comAlliancebernstein L.P. Acquires New Stake in NewAmsterdam Pharma (NASDAQ:NAMS)Alliancebernstein L.P. bought a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 1,858,065 shares of the company's stock, valued at approximately $47,7April 7, 2025 | marketbeat.comWellington Management Group LLP Acquires 2,222,900 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)Wellington Management Group LLP raised its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 2,410.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,315,123 shares of the company's stock after acquiring an additionaApril 7, 2025 | marketbeat.comPamalican Asset Management Ltd Makes New Investment in NewAmsterdam Pharma (NASDAQ:NAMS)Pamalican Asset Management Ltd purchased a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 30,000 shares of the company's stoApril 6, 2025 | marketbeat.comCinctive Capital Management LP Sells 57,055 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)Cinctive Capital Management LP trimmed its position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 85.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 9,516 shares of the company's stock after selling 57,055 shares during the qApril 6, 2025 | marketbeat.comNewAmsterdam Pharma Co NV (NAMS) Announces Inducement Share Options for New HiresApril 4, 2025 | gurufocus.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 4, 2025 | globenewswire.comAmerican Century Companies Inc. Acquires Shares of 346,572 NewAmsterdam Pharma (NASDAQ:NAMS)American Century Companies Inc. acquired a new stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 346,572 shares of the coApril 4, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Sees Unusually-High Trading Volume - Here's WhyNewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Volume Increase - Here's WhyApril 3, 2025 | marketbeat.comNewAmsterdam Pharma is Now Oversold (NAMS)April 3, 2025 | nasdaq.comNAMS Crosses Below Key Moving Average LevelApril 2, 2025 | nasdaq.comPiper Sandler Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)April 2, 2025 | markets.businessinsider.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Down 8.5% - Time to Sell?NewAmsterdam Pharma (NASDAQ:NAMS) Shares Down 8.5% - Here's What HappenedApril 1, 2025 | marketbeat.comWilliam Blair Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)April 1, 2025 | markets.businessinsider.comPictet Asset Management Holding SA Buys 140,605 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)Pictet Asset Management Holding SA increased its stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 13.8% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,157,452 shares of the company's stock after purchasing an addApril 1, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Growth in Short InterestNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) saw a large growth in short interest in March. As of March 15th, there was short interest totalling 4,340,000 shares, a growth of 42.8% from the February 28th total of 3,040,000 shares. Currently, 7.5% of the shares of the stock are sold short. Based on an average daily volume of 843,800 shares, the short-interest ratio is presently 5.1 days.March 31, 2025 | marketbeat.comNewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | gurufocus.comNewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Swiss National BankSwiss National Bank lifted its holdings in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 105.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 72,000 shares of the company's stock after buying an additional 36,900 shares during the perioMarch 30, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Director Buys $25,526.15 in StockNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) Director James N. Topper acquired 1,135 shares of the firm's stock in a transaction that occurred on Wednesday, March 26th. The shares were bought at an average price of $22.49 per share, for a total transaction of $25,526.15. Following the completion of the purchase, the director now owns 3,013,569 shares in the company, valued at $67,775,166.81. This trade represents a 0.04 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.March 29, 2025 | marketbeat.comJames N. Topper Buys 1,135 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) StockMarch 29, 2025 | insidertrades.comDirector Makes Bold Move with NewAmsterdam Pharma Stock Purchase!March 28, 2025 | tipranks.comDCF Advisers LLC Grows Position in NewAmsterdam Pharma (NASDAQ:NAMS)DCF Advisers LLC increased its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 162.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 89,400 shares of the company's stock after buying an additional 55,400 shares during thMarch 22, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Trading 3.4% Higher - What's Next?NewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 3.4% - Here's WhyMarch 21, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Sold by US Bancorp DEUS Bancorp DE cut its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 80.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,804 shares of the company's stock after selling 11,619 shares during the period. US Bancorp DE's holdingsMarch 18, 2025 | marketbeat.comNewAmsterdam Pharma Company (NAMS) Gets a Buy from Piper SandlerMarch 12, 2025 | markets.businessinsider.comNewAmsterdam Pharma (NASDAQ:NAMS) Receives Consensus Rating of "Buy" from BrokeragesNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six ratings firms that are currently covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1 year price target among anMarch 11, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Director James N. Topper Purchases 4,005 SharesNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) Director James N. Topper bought 4,005 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The shares were purchased at an average cost of $21.02 per share, for a total transaction of $84,185.10. Following the acquisition, the director now owns 3,012,434 shares of the company's stock, valued at $63,321,362.68. This represents a 0.13 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.March 7, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Volume Increase - Time to Buy?NewAmsterdam Pharma (NASDAQ:NAMS) Sees Strong Trading Volume - Should You Buy?March 7, 2025 | marketbeat.comInsider Buying: NewAmsterdam Pharma (NASDAQ:NAMS) Director Buys 4,005 Shares of StockMarch 7, 2025 | insidertrades.com Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address NAMS Media Mentions By Week NAMS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NAMS News Sentiment▼1.200.73▲Average Medical News Sentiment NAMS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NAMS Articles This Week▼125▲NAMS Articles Average Week Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Lantheus News Revolution Medicines News BridgeBio Pharma News TG Therapeutics News Legend Biotech News Telix Pharmaceuticals Limited American Depositary Shares News Sarepta Therapeutics News Blueprint Medicines News Axsome Therapeutics News Nuvalent News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NAMS) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NAMS Stock Free NAMS Stock Alerts